Elonva
corifollitropin alfa
Keep this leaflet. You may need to read it again.
If you have any further questions, ask your doctor or pharmacist.
This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side
effects not listed in this leaflet. See section 4.
What Elonva is and what it is used for
What you need to know before you use Elonva
How to use Elonva
Possible side effects
How to store Elonva
Contents of the pack and other information
Elonva contains the active ingredient corifollitropin alfa and belongs to the group of medicines called gonadotropic hormones. Gonadotropic hormones play an important role in human fertility and reproduction. One of these gonadotropic hormones is Follicle Stimulating Hormone (FSH), which is needed in women for the growth and development of follicles (small round sacs in your ovaries that contain the eggs) and in adolescent males (14 years and older) for treatment of delayed puberty due to hypogonadotropic hypogonadism (HH), in combination with a medicine called human Chorionic Gonadotropin (hCG).
In women
Elonva is used to help achieve pregnancy in women having infertility treatment, such as in vitro fertilisation (IVF). IVF involves collecting the eggs from the ovary, fertilising them in the laboratory, and transferring the embryos into the uterus a few days later. Elonva causes the growth and development of several follicles at the same time by a controlled stimulation of the ovaries.
In adolescent males (14 years and older)
Elonva is used to bring about the development and function of the testes and induce the development of male sexual characteristics in adolescent males with delayed puberty due to HH.
are allergic (hypersensitive) to corifollitropin alfa or any of the other ingredients of this medicine (listed in section 6)
have cancer of the ovary, breast, uterus, or brain (pituitary gland or hypothalamus)
have recently had unexpected vaginal bleeding, other than menstrual, without a diagnosed cause
have ovaries that do not work because of a condition called primary ovarian failure
have ovarian cysts or enlarged ovaries
have malformations of the sexual organs which make a normal pregnancy impossible
have fibroid tumours in the uterus which make a normal pregnancy impossible
have risk factor of OHSS (OHSS is a serious medical problem that can happen when the ovaries are overly stimulated. See below for further explanation.):
have polycystic ovarian syndrome (PCOS)
have had ovarian hyperstimulation syndrome (OHSS)
have previously had a treatment cycle of controlled stimulation of the ovaries that
resulted in the growth of more than 30 follicles with a size of 11 mm or larger
have a basal antral follicle count (the number of small follicles present in your ovaries at the beginning of a menstrual cycle) higher than 20
Talk to your doctor before using Elonva. Ovarian hyperstimulation syndrome (OHSS)
Treatment with gonadotropic hormones like Elonva may cause ovarian hyperstimulation syndrome (OHSS). This is a serious medical condition where the ovaries are overly stimulated and the growing
follicles become larger than normal. In rare cases, severe OHSS may be life-threatening. Therefore,
close supervision by your doctor is very important. To check the effects of treatment, your doctor will do ultrasound scans of your ovaries. Your doctor may also check blood hormone levels. (See also
section 4.)
OHSS causes fluid to build up suddenly in your stomach and chest areas and can cause blood clots to form. Call your doctor right away if you have:
severe abdominal swelling and pain in the stomach area (abdomen)
feeling sick (nausea)
vomiting
sudden weight gain due to fluid build up
diarrhoea
decreased urine output
trouble breathing
You may use Elonva only once during the same treatment cycle, otherwise, the chance of having OHSS may increase.
Before starting to use this medicine, tell your doctor if you have ever had ovarian hyperstimulation syndrome (OHSS).
Ovarian torsion
Ovarian torsion is the twisting of an ovary. Twisting of the ovary could cause the blood flow to the ovary to be cut off.
Before starting to use this medicine, tell your doctor if you:
have ever had ovarian hyperstimulation syndrome (OHSS).
are pregnant or think that you may be pregnant.
have ever had stomach (abdominal) surgery.
have ever had a twisting of an ovary.
have past or current cysts in your ovary or ovaries.
Blood clot (Thrombosis)
Treatment with gonadotropic hormones like Elonva may (just as pregnancy) increase the risk of having a blood clot (thrombosis). Thrombosis is the formation of a blood clot in a blood vessel.
Blood clots can cause serious medical conditions, such as:
blockage in your lungs (pulmonary embolus)
stroke
heart attack
blood vessel problems (thrombophlebitis)
a lack of blood flow (deep venous thrombosis) that may result in a loss of your arm or leg.
Please discuss this with your doctor, before starting treatment, especially if:
you know you already have an increased chance of having a thrombosis
you, or anyone in your immediate family, have ever had a thrombosis
you are severely overweight.
Multiple births or birth defects
There is an increased chance of having twins or even more than two babies, even when only one embryo is transferred into the uterus. Multiple pregnancies carry an increased health risk for both the mother and her babies. Multiple pregnancies and specific characteristics of couples with fertility problems (e.g., a woman’s age, certain sperm problems, genetic background of both parents) may also be associated with an increased chance of birth defects.
Pregnancy complications
If treatment with Elonva results in pregnancy, there is a higher chance of pregnancy outside the uterus (an ectopic pregnancy). Therefore, your doctor should perform an early ultrasound examination to exclude the possibility of pregnancy outside the uterus.
Ovarian and other reproductive system tumours
There have been reports of ovarian and other reproductive system tumours in women who have had infertility treatment. It is not known if treatment with fertility medicines increases the risk of these tumours in infertile women.
Other medical conditions
In addition, before starting to use this medicine, tell your doctor if you:
have kidney disease.
have uncontrolled pituitary gland or hypothalamic problems.
have an underactive thyroid gland (hypothyroidism).
have adrenal glands that are not working properly (adrenocortical insufficiency).
have high prolactin levels in the blood (hyperprolactinemia).
have any other medical conditions (for example, diabetes, heart disease, or any other long-term disease).
have been told by a doctor that pregnancy would be dangerous for you.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.
If you do a pregnancy test during your infertility treatment with Elonva, the test might wrongly suggest that you are pregnant. Your doctor will advise you at what time you can start performing pregnancy tests. In case of a positive pregnancy test, contact your doctor.
You should not use Elonva if you are already pregnant, or think that you might be pregnant, or if you are breast-feeding.
Ask your doctor or pharmacist for advice before taking this medicine.
Elonva may cause dizziness. If you feel dizzy, you should not drive or use machines.
This medicinal product contains less than 1 mmol sodium (23 mg) per injection, that is to say essentially ‘sodium-free’.
Always use Elonva exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
In women
Elonva is used in women having infertility treatment like in vitro fertilisation (IVF). During this treatment, Elonva is used in combination with a medicine (so called GnRH-antagonist) to prevent your
ovary from releasing an egg too early. Treatment with the GnRH-antagonist usually starts 5 to 6 days after the injection of Elonva.
The use of Elonva in combination with a GnRH agonist (another medicine to prevent your ovary from releasing an egg too early) is not recommended.
In adolescent males (14 years and older)
Elonva in combination with a medicine called hCG, is used for treatment of delayed puberty due to HH. Elonva should be administered once every two weeks, in the morning on the same day of the week.
Women
In the treatment of women of reproductive age, the dose of Elonva is based on weight and age.
A single 100-microgram dose is recommended in women who weigh less than or equal to 60 kilograms and who are 36 years of age or younger.
A single 150-microgram dose is recommended in women:
who weigh more than 60 kilograms, regardless of age.
who weigh 50 kilograms or more and who are older than 36 years of age. Women older than 36 years of age who weighed less than 50 kilograms were not studied.
Body Weight | ||||
Less than 50 kg | 50 – 60 kg | More than 60 kg | ||
Age | 36 years or younger | 100 micrograms | 100 micrograms | 150 micrograms |
Older than 36 years | Not studied | 150 micrograms | 150 micrograms | |
During the first seven days after the injection with Elonva, you should not use (recombinant) Follicle Stimulating Hormone ((rec)FSH). Seven days after the injection of Elonva, your doctor may decide to continue your stimulation cycle with another gonadotropic hormone, like (rec)FSH. This may be continued for a few days until enough follicles of adequate size are present. This can be checked by ultrasound examination. Treatment with (rec)FSH is then stopped and the eggs are matured by giving hCG (human Chorionic Gonadotropin). The eggs are collected from the ovary 34-36 hours later.
In adolescent males (14 years and older)
The dose of Elonva is based on body weight:
For adolescent males weighing less than or equal to 60 kg
100 micrograms of Elonva once every two weeks for 12 weeks, followed by administration of Elonva (once every 2 weeks) with hCG. If your body weight increases to greater than 60 kg
during treatment, your doctor may increase your dose of Elonva to 150 micrograms.
For adolescent males weighing more than 60 kg
150 micrograms of Elonva once every two weeks for 12 weeks, followed by administration of Elonva (once every 2 weeks) with hCG.
The combination therapy with hCG twice weekly (500 – 5000 IU) may be necessary for 52 weeks or longer to achieve adult gonadal development.
Treatment with Elonva should be supervised by a physician experienced in the treatment of fertility problems. Elonva must be injected under the skin (subcutaneously) into a skin fold (that you pinch between your thumb and index finger), preferably just below the navel. The injection may be given by a healthcare professional (for example a nurse), your partner or yourself, if carefully instructed by your doctor. Always use Elonva exactly as your doctor has told you. You should check with your doctor or pharmacist if you are unsure. A step-by-step “instructions for use” is given at the end of this leaflet.
Do not inject Elonva into a muscle.
Elonva is supplied in pre-filled syringes that have an automatic safety system to help prevent needle stick injuries after use.
If you think you have used more Elonva or (rec)FSH than you should, contact your doctor immediately.
If you forgot to inject Elonva on the day you should have, contact your doctor immediately. Do not inject Elonva without talking with your doctor.
If you have any further questions on the use of this medicine, ask your doctor.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
A possible complication of treatment with gonadotropic hormones like Elonva is unwanted overstimulation of the ovaries. The chance of having this complication can be reduced by carefully monitoring the number of maturing follicles. Your doctor will do ultrasound scans of your ovaries to carefully monitor the number of maturing follicles. Your doctor may also check blood hormone levels. The first symptoms of ovarian overstimulation may be noticed as pain in the stomach (abdomen), feeling sick or diarrhoea. Ovarian overstimulation may develop into a medical condition called ovarian hyperstimulation syndrome (OHSS), which can be a serious medical problem. In more severe cases this may lead to enlargement of the ovaries, collection of fluid in the abdomen and/or chest (which may cause sudden weight gain due to fluid buildup) or clots in the blood vessels.
Contact your doctor without delay if you have pain in the stomach (abdomen) or any of the other symptoms of ovarian hyperstimulation, even if they occur some days after the injection has been given.
The chance of having a side effect is described by the following categories:
Ovarian hyperstimulation syndrome (OHSS)
Pelvic pain
Feeling sick (nausea)
Headache
Pelvic discomfort
Breast tenderness
Tiredness (fatigue)
Twisting of an ovary (ovarian torsion)
Liver enzyme increases
Miscarriage
Pain after oocyte retrieval
Procedural pain
Releasing an egg too early (premature ovulation)
Abdominal distension
Vomiting
Diarrhoea
Constipation
Back pain
Breast pain
Bruising or pain at the injection site
Irritability
Mood swings
Dizziness
Hot flush
- Allergic reactions (hypersensitivity reactions, both local and generalised, including rash).
Pregnancy outside the uterus (an ectopic pregnancy) and multiple pregnancies have also been reported. These side effects are not considered to be related to the use of Elonva, but to Assisted Reproductive Technology (ART) or subsequent pregnancy.
In rare instances, blood clots (thrombosis) that formed inside a blood vessel, broke off, and travelled inside the bloodstream to block another blood vessel (thromboembolism) have been associated with Elonva therapy as with other gonadotropins.
If you are an adolescent male
Vomiting
Injection site pain
Hot flush
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label and outer carton after “EXP” (expiry date). The expiry date refers to the last day of that month.
Store in a refrigerator (2ºC-8°C). Do not freeze.
There are two options:
Store in a refrigerator (2ºC-8°C). Do not freeze.
Store at or below 25ºC for a period of not more than one month. Make a note of when you start storing the product out of the refrigerator, and use it within one month of that date.
Keep the syringe in the outer carton in order to protect from light.
if it has been stored out of the refrigerator for more than one month.
if it has been stored out of the refrigerator at a temperature of more than 25ºC.
if you notice that the solution is not clear.
if you notice that the syringe or the needle is damaged.
Do not throw away an empty or unused syringe via household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
The active substance is corifollitropin alfa. Each Elonva 100 micrograms solution for injection pre-filled syringe contains 100 micrograms in 0.5 millilitre (mL) solution for injection. Each
Elonva 150 micrograms solution for injection pre-filled syringe contains 150 micrograms in
0.5 millilitre (mL) solution for injection.
The other ingredients are: sodium citrate, sucrose, polysorbate 20, methionine and water for injections. The pH may have been adjusted with sodium hydroxide and/or hydrochloric acid.
Elonva is a clear and colourless aqueous solution for injection (injection) in a pre-filled syringe with an automatic safety system, which prevents needle stick injuries after use. The syringe is packed together with a sterile injection needle. Each syringe contains 0.5 mL solution.
One pre-filled syringe is available in a single pack.
Elonva is available in two strengths: 100 micrograms and 150 micrograms solution for injection.
N.V. Organon Kloosterstraat 6
5349 AB Oss
The Netherlands
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Organon Belgium
Tél/Tel: 0080066550123 (+32 2 2418100)
Organon Pharma B.V. Lithuania atstovybė Tel.: +370 52041693
Органон (И.А.) Б.В. - клон България Тел.: +359 2 806 3030
Organon Belgium
Tél/Tel: 0080066550123 (+32 2 2418100)
Organon Czech Republic s.r.o. Tel: +420 233 010 300
Organon Hungary Kft.
Tel.: +36 1 766 1963
Organon Denmark ApS Tlf: +45 4484 6800
Organon Pharma B.V., Cyprus branch Tel: +356 2277 8116
Organon Healthcare GmbH
Tel.: 0800 3384 726 (+49 (0) 89 2040022 10)
Organon
Tel: 00800 66550123
(+32 2 2418100)
Organon Pharma B.V. Estonian RO Tel: +372 66 61 300
Organon Norway AS Tlf: +47 24 14 56 60
BIANEΞ Α.Ε.
Τηλ: +30 210 80091 11
Organon Austria GmbH Tel: +43 (0) 1 263 28 65
Organon Salud, S.L.
Tel: +34 91 591 12 79
Organon Polska Sp. z o.o. Tel.: +48 22 105 50 01
Organon France
Tél: +33 (0) 1 57 77 32 00
Organon Portugal, Sociedade Unipessoal Lda.
Tel: +351 218705500
Organon Pharma d.o.o. Tel: +385 1 638 4530
Organon Biosciences S.R.L. Tel: +40 21 527 29 90
Organon Pharma (Ireland) Limited Tel: +353 15828260
Organon Pharma B.V., Oss, podružnica Ljubljana
Tel: +386 1 300 10 80
Vistor hf.
Sími: + 354 535 7000
Organon Italia S.r.l.
Tel: +39 06 3336407
Organon Finland Oy
Puh/Tel: +358 (0) 29 170 3520
Organon Pharma B.V., Cyprus branch
Τηλ: +357 22866730
Organon Sweden AB Tel: +46 8 502 597 00
Ārvalsts komersanta “Organon Pharma B.V.” pārstāvniecība
Tel: +371 66968876
1.
Wash your hands with soap and water and dry them before you use Elonva.
Swab the injection site (the area just below your belly button) with
a disinfectant (for example, alcohol) to remove any surface bacteria.
Clean about 5 cm around the point where the needle will go in and
let the disinfectant dry for at least one minute before proceeding.
2.
While waiting for the disinfectant to dry, break the label perforation and pull off the needle-cap
Leave the needle shield on the needle
Place the needle shield (containing the needle) on a clean dry surface, while preparing the syringe.
3.
Hold the syringe with the grey cap pointing upwards
Tap the syringe gently with your finger to help air bubbles rise to the top.
4.
Keep the syringe pointing upwards
Unscrew the syringe cap counter-clockwise.
5.
Keep the syringe pointing upwards
Screw the needle shield (containing the needle) clockwise onto the syringe.
6.
Keep the syringe pointing upwards
Remove the needle shield straight up and discard it
7.
Now take the syringe between index and middle finger in the upward position
Place your thumb on the plunger
Carefully push the plunger upwards until a tiny droplet appears at the tip of the needle.
8.
Pinch a fold of the skin between thumb and index finger
Insert the entire needle at an angle of 90 degrees into the fold of the skin
CAREFULLY press the plunger until it cannot go further and hold
the plunger down
COUNT TO FIVE to ensure that all of the solution is injected.
9.
Release your thumb from the plunger
The needle will withdraw automatically into the syringe where it will be locked permanently.